Clinical trials: Embryonal Neoplasm
- Condition Embryonal Neoplasm
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Cutaneous Melanoma, Stage II, Malignant Cutaneous Melanoma
Evaluation of Oncoxin-Viusid® in Cutaneous Melanoma
Malignant melanoma, responsible for 75% of deaths from skin cancer. Current therapeutic options have poor response, many adverse events and high costs.
- Conditions
- Cutaneous Melanoma, Stage II, Malignant Cutaneous Melanoma, Cutaneous Melanoma, Stage III
- Trial name
- NCT03541148
- Testing
- Oncoxin-Viusid
- Where
- Cuba
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Catalysis SL
Melanoma, BRAF V600 Mutation
Bioequivalence Binimetinib 3 x 15 mg and 45 mg Formulations
The current commercially available MEKTOVI® (binimetinib) 15 mg tablets are provided as immediate release film-coated tablets for oral administration.
- Conditions
- Melanoma, BRAF V600 Mutation, Unresectable Melanoma, Metastatic Melanoma
- Trial name
- NCT05810740
- Testing
- Binimetinib 15 MG, Binimetinib 45 MG
- Where
- France
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Pierre Fabre Medicament
Skin Cancer Melanoma
AI-Driven Early Detection of Skin Cancer
This study evaluates the feasibility and accuracy of an AI-powered mobile platform (NuvanaDx) for early detection of skin cancer, including melanoma, using smartphone-based imaging.
- Trial name
- Skin Cancer (NCT07144306)
- Testing
- Smartphone-based AI skin lesion analysis (NuvanaDx platform).
- Where
- United Kingdom
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Nuvana Healthcare LTD
Melanoma, Healthy Volunteers
Polish Microbiome Map
Knowledge about the correlations between the composition of the gut microbiome and a wide range of diseases has substantially increased in recent years.
- Conditions
- Melanoma, Healthy Volunteers, Microbiome, Metagenome
- Trial name
- NCT04169867
- Testing
- Collection of stool samples
- Where
- Poland
- Volunteers
- 1,160 people, healthy volunteers welcome
- Sponsor
- Ardigen
Glioblastoma Multiforme
Convection Enhanced Localized Administration of PRX321 With Real-time Imaging for Therapy of Recurrent Glioblastoma (CLARITY-1)
A Phase II, multi-center, open-label, single-arm study in up to 42 subjects with first recurrence or progression of GBM at up to 12 sites in Australia, Europe, Israel, and the United States.
- Trial name
- CLARITY-1 (NCT00797940)
- Testing
- IL-4PE
- Volunteers
- healthy volunteers welcome
- Sponsor
- Sophiris Bio Corp
All Diagnosed Health Conditions, ADD/ADHD
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
We are the missing link in clinical trials, connecting patients and researchers seamlessly and conveniently using a mobile health platform to advance medical research.
- Conditions
- All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis
- Trial name
- NCT01931644
- Where
- United States
- Volunteers
- 17,667 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
Melanoma
Moletest Clinical Study in Scotland
To evaluate an iPad based photoimage analysis system (Moletest) for improving discrimination of benign from malignant suspicious skin lesions or moles.
- Trial name
- NCT02196246
- Where
- United Kingdom
- Volunteers
- 1,120 people, healthy volunteers welcome
- Sponsor
- Moletest Scotland Ltd
Melanoma
Does the Aid of MelaFind Affect Clinical Management Decisions
The objective of this study is to determine and compare the performance of dermatologists (in Germany) on the excision decision against the performance of MelaFind, a non-invasive and objective multi-spectral computer vision…
- Trial name
- NCT01387581
- Where
- United States
- Volunteers
- 227 people, healthy volunteers welcome
- Sponsor
- MELA Sciences, Inc.
Melanoma
Randomized Trial of ATN-224 and Temozolomide in Advanced Melanoma
This is a multicenter, randomized, phase II study to evaluate the safety and efficacy of oral ATN-224 plus temozolomide in patients with advanced melanoma.
- Trial name
- NCT00383851
- Testing
- ATN-224, Temozolomide
- Where
- 17 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Attenuon
Melanoma, Circulating Tumor Cells
In Vivo Liquid Biopsy of Melanoma (Cytophone)
The Cytophone is a first in the world patented system to identify and count single circulating melanoma cells in blood circulation inside the human body.
- Conditions
- Melanoma, Circulating Tumor Cells, Metastatic Melanoma, Diagnosis
- Trial name
- Cytophone (NCT06488365)
- Testing
- Cytophone
- Where
- United States
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Cytoastra
Pregnancy Complications, Pregnancy Outcome
BioThrax® (Anthrax) Vaccine in Pregnancy Registry
The purpose of this study is to determine if inadvertent receipt of the BioThrax vaccine during pregnancy is independently associated with adverse maternal, pregnancy, or infant health outcomes.
- Conditions
- Pregnancy Complications, Pregnancy Outcome, Congenital Abnormalities
- Trial name
- NCT01653392
- Testing
- Observational Intervention
- Where
- United States
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- Emergent BioSolutions
Melanoma
Evaluation of Pigmented Skin Lesions With MelaFind(R) System
The purpose of this clinical trial is to demonstrate that MelaFind®, a new instrument that uses machine vision for non-invasive early detection of cutaneous pigmented malignant melanoma, is safe and effective.
- Trial name
- NCT00434057
- Testing
- MelaFind(R)
- Where
- 2 sites in United States
- Volunteers
- 1,383 people, healthy volunteers welcome
- Sponsor
- MELA Sciences, Inc.
Melanoma
Survey Study - Sensitivity Comparison Between MelaFind and Physician Group
This survey study purposes to determine and compare the biopsy/referral sensitivity and specificity of MelaFind to the average biopsy/referral sensitivity and specificity of dermatologists.
- Trial name
- NCT01011153
- Volunteers
- 241 people, healthy volunteers welcome
- Sponsor
- MELA Sciences, Inc.
Neuroendocrine Tumor, Carcinoid
RegisterNET - A Registry for Neuroendocrine Tumors in the USA and Worldwide
Neuroendocrine tumors are derived from the neuroendocrine system of the gastroenteropancreatic and bronchopulmonary tract systems.
- Conditions
- Neuroendocrine Tumor, Carcinoid, Neuroendocrine Carcinoma
- Trial name
- RegisterNET (NCT02270567)
- Testing
- NETest
- Where
- United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Wren Laboratories LLC
Melanoma, BRAF V600 Mutation
Relative Bioavailability of Binimetinib 3 x 15 mg and 45 mg Formulations
The current commercially available MEKTOVI® (binimetinib) 15 mg tablets are provided as immediate release film-coated tablets for oral administration.
- Conditions
- Melanoma, BRAF V600 Mutation, Unresectable Melanoma, Metastatic Melanoma
- Trial name
- NCT05103891
- Testing
- Binimetinib Oral Tablet
- Where
- France
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Pierre Fabre Medicament
Glioma, 18F-Fluoroethyl-l-tyrosine
Clinical Benefit of 18F-FET in Glioma.
This Phase II clinical trial, sponsored by Primo Biotechnology Co., Ltd., evaluates the clinical benefit of $^{18}$F-FET PET/CT in diagnosing glioma.
- Trial name
- NCT07698457
- Testing
- 18F-Fluoroethyl-l-tyrosine
- Where
- 4 sites in Taiwan
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Primo Biotechnology Co., Ltd
Colorectal Cancer, Pancreatic Adenocarcinoma
Circulating Tumor DNA Exposure in Peripheral Blood
This is a prospective, multi-center, blinded feasibility study. The objective of this study is to test the feasibility of the detection of tumor DNA of a variety of tumors in peripheral blood using a novel process for the…
- Conditions
- Colorectal Cancer, Pancreatic Adenocarcinoma, Gastric Cancer, Hepatocellular Carcinoma
- Trial name
- NCT03517332
- Where
- 6 sites in United States, Switzerland
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Quantgene Inc.
Glioblastoma Multiforme
Safety Study of the Combination of Tandutinib With Temozolomide and Bevacizumab After Radiation and Temozolomide in Patients With Newly Diagnosed With Glioblastoma Multiforme
This is a safety study of tandutinib in combination with temozolomide and bevacizumab after people have received radiation therapy and temozolomide treatment.
- Trial name
- NCT00904852
- Testing
- Tandutinib, bevacizumab, and temozolomide
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Millennium Pharmaceuticals, Inc.
Brest Cancer, Lung Cancer (NSCLC)
The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cell Transcriptomic Profiling
The purpose of the CCANED-CIPHER study is to develop and validate an AI-based blood test for early cancer detection and to monitor treatment effectiveness in cancer patients.
- Conditions
- Brest Cancer, Lung Cancer (NSCLC), Pancreatic Cancer, Adult, Prostate Cancers
- Trial name
- CCANED-CIPHER (NCT06717295)
- Testing
- DiNanoQ: A multi-cancer early detection (MCED) blood test, DiNanoTrack: Therapeutic Response Monitoring Blood Test
- Where
- 4 sites in Argentina, Nigeria and 1 more
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- Javier Toledo
Medullary Thyroid Cancer
Study in Healthy Volunteers to Assess Effect of Omeprazole and Ranitidine on the Pharmacokinetics of Vandetanib
Study in healthy volunteers to assess effect of omeprazole and ranitidine on the pharmacokinetics of vandetanib
- Trial name
- Vandetanib (NCT01539655)
- Testing
- vandetanib, omeprazole, ranitidine
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Sanofi